Short telomeres are a risk factor for idiopathic pulmonary fibrosis
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Idiopathic interstitial pneumonias (IIPs) have a progressive and often fatal course, and their enigmatic etiology has complicated approaches to effective therapies. Idiopathic pulmonary fibrosis (IPF) is the most common of IIPs and shares with IIPs an increased incidence with age and unexplained scarring in the lung. Short telomeres limit tissue renewal capacity in the lung and germ-line mutations in telomerase components, hTERT and hTR , underlie inheritance in a subset of families with IPF. To examine the hypothesis that short telomeres contribute to disease risk in sporadic IIPs, we recruited patients who have no family history and examined telomere length in leukocytes and in alveolar cells. To screen for mutations, we sequenced hTERT and hTR. We also reviewed the cases for features of a telomere syndrome. IIP patients had shorter leukocyte telomeres than age-matched controls ( P < 0.0001). In a subset (10%), IIP patients had telomere lengths below the first percentile for their age. Similar to familial cases with mutations, IPF patients had short telomeres in alveolar epithelial cells ( P < 0.0001). Although telomerase mutations were rare, detected in 1 of 100 patients, we identified a cluster of individuals (3%) with IPF and cryptogenic liver cirrhosis, another feature of a telomere syndrome. Short telomeres are thus a signature in IIPs and likely play a role in their age-related onset. The clustering of cryptogenic liver cirrhosis with IPF suggests that the telomere shortening we identify has consequences and can contribute to what appears clinically as idiopathic progressive organ failure in the lung and the liver.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, patients with IPF who have mutant telomerase genes are at an increased risk of developing bone marrow failure and liver disease54,71.”
From The telomere syndromes (2012) · cites this paper as [54]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, telomere dysfunction in epithelial cells, or perhaps another cell type, might cause parenchymal organ remodelling, which manifests as fibrosis and/or emphysema46,54,99.”
From The telomere syndromes (2012) · cites this paper as [54]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Moreover, circulating leukocytes and alveolar epithelial cells show shorter telomeres than age-matched individuals53.”
From Telomere dysfunction in ageing and age-related diseases (2022) · cites this paper as [53]
The cited source says what the claim attributes to it.
In the citing paper
“The frequency of these mutations is highest in individuals with the progressive disorder IPF, which accounts for 8–15% of familial and 1–3% of sporadic cases54,56,68,69.”
From The telomere syndromes (2012) · cites this paper as [54]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Lead SNPs at two loci (TERC and TERT) associate with several cancers and other diseases, including idiopathic pulmonary fibrosis.”
From Identification of seven loci affecting mean telomere length and their association with disease (2013) · cites this paper as [26]
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Telomeres shorten during ageing of human fibroblasts
Harley, C. B., Futcher, A. B., & Greider, C. W. (1990) · Nature · doi:10.1038/345458a0 · Cited by 5,750
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Identification of a specific telomere terminal transferase activity in tetrahymena extracts
Greider, C. W., & Blackburn, E. H. (1985) · Cell · doi:10.1016/0092-8674(85)90170-9 · Cited by 3,400
A DNA damage checkpoint response in telomere-initiated senescence
Fagagna, F. D. D., Reaper, P. M., Clay-Farrace, L., Fiegler, H., Carr, P., von Zglinicki, T., Saretzki, G., Carter, N. P., & Jackson, S. P. (2003) · Nature · doi:10.1038/nature02118 · Cited by 2,917
Telomerase Catalytic Subunit Homologs from Fission Yeast and Human
Nakamura, T. M., Morin, G. B., Chapman, K. B., Weinrich, S. L., Andrews, W. H., Lingner, J., Harley, C. B., & Cech, T. R. (1997) · Science · doi:10.1126/science.277.5328.955 · Cited by 2,256
Telomere Shortening and Tumor Formation by Mouse Cells Lacking Telomerase RNA
Blasco, M. A., Lee, H.-W., Hande, M. P., Samper, E., Lansdorp, P. M., DePinho, R. A., & Greider, C. W. (1997) · Cell · doi:10.1016/s0092-8674(01)80006-4 · Cited by 2,108
Self-citationTelomerase Mutations in Families with Idiopathic Pulmonary Fibrosis
Armanios, M. Y., Chen, J. J.-L., Cogan, J. D., Alder, J. K., Ingersoll, R. G., Markin, C., Lawson, W. E., Xie, M., Vulto, I., Phillips, J. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066157 · Cited by 1,357 · cited 6×
“In IPF families with telomerase mutations, cases of aplastic anemia can be hidden and are uncovered after a thorough family history, suggesting that mutations in telomerase have heterogeneous manifestations in an individual patient and within families, and that a subset of families with IPF falls on the same spectrum…”
BackgroundInfluentialSelf-citationEssential role of mouse telomerase in highly proliferative organs
Lee, H.-W., Blasco, M. A., Gottlieb, G. J., Horner, J. W., Greider, C. W., & DePinho, R. A. (1998) · Nature · doi:10.1038/33345 · Cited by 1,270
A telomerase component is defective in the human disease dyskeratosis congenita
Mitchell, J. R., Wood, E., & Collins, K. (1999) · Nature · doi:10.1038/990141 · Cited by 1,168
Greider, C. W., & Blackburn, E. H. (1987) · Cell · doi:10.1016/0092-8674(87)90576-9 · Cited by 1,150
Cited by
Items 601–700 of 802
Burgess, J. K., Muizer, K., Brandsma, C., & Heijink, I. H. (2018) · Molecular and translational medicine · doi:10.1007/978-3-319-98143-7_9 · Cited by 4
Tomlinson, C. G., Sasa, G., Aubert, G., Martin‐Giacalone, B. A., Plon, S. E., Bryan, T. M., Bertuch, A. A., & Gramatges, M. M. (2020) · Leukemia · doi:10.1038/s41375-020-0835-8 · Cited by 4
Zhang, K., Wang, L., Chen, H., Shi, Y., Liu, Y., Liu, J., Hong, X., & Liu, J. (2021) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13472 · Cited by 4
RetractedInterstitial lung disease in elderly
Dvoretskiy, L. I. (2014) · PULMONOLOGIYA · doi:10.18093/0869-0189-2014-0-4-91-99 · Cited by 5
“Аномально укороченные теломеры были выявлены в альвеолярном эпителии у пациентов с ИЛФ [33], а генные мутации фермен та, ответственного за поддержание длины теломер (теломеразы) ассоциировались с наследственной формой ИЛФ [34].”
Another building in the IPF Manhattan plot skyline
Alder, J. K., & Kass, D. J. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30394-6 · Cited by 4
Self-citationRisk Factors and Biomarkers of RA-ILD
Doyle, T. J., Dellaripa, P. F., & Rosas, I. O. (2017) · Respiratory medicine · doi:10.1007/978-3-319-68888-6_5 · Cited by 4
[The effect of deep branches of cervical nerve on motorial function of trapezius muscle].
Wang, F., Wen, Y., & Li, L. (2003) · 华西口腔医学杂志 · Cited by 4
Whole-Exome Sequencing Insights into Adult Pulmonary Fibrosis. Repeating the Telomere Theme
Garcia, C. K. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201701-0194ed · Cited by 4
The Genetics of Interstitial Lung Diseases
Borie, R., Guen, P. L., Ghanem, M., Taillé, C., Mathai, S. K., Dieudé, P., Kannengiesser, C., & Crestani, B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11453-9 · Cited by 4
Shortened Telomere Length as a Risk Factor for Idiopathic Pulmonary Fibrosis: A Meta-Analysis
Fachrucha, F., Syuaib, F. I., Purwono, A., Nurwidya, F., Andarini, S., Burhan, E., & Wiyono, W. H. (2025) · The Open Respiratory Medicine Journal · doi:10.2174/0118743064421488251017061020 · Cited by 3
Okyar, B., Yüce, S., Karacan, E., Arıcı, F. N., Yıldırım, A., Koç, E., Tüzün, Z., Sibel, K. A. R. A., Dılek, O., Sümbül, H. E., et al. (2025) · Rheumatology International · doi:10.1007/s00296-025-06056-2 · Cited by 3
“Inde-pendently, telomere biology disorders provide a genetic link between pulmonary fibrosis and hepatic disease, supporting a systemic substrate [14].”
Immunological mechanisms and therapeutic approaches in pulmonary fibrosis
Nell, L. M., Hendriks, R. W., Wijsenbeek, M. S., Corneth, O. B. J., & Koudstaal, T. (2026) · European Respiratory Review · doi:10.1183/16000617.0227-2025 · Cited by 5
“Around 80% affect epithelial integrity or telomere biology, such as the MUC5B (mucin 5B) promoter variant and TERT/TERC (telomerase reverse transcriptase/telomerase RNA component) mutations [25, 26].”
Interstitial and Restrictive Pulmonary Disorders
Lawson, W. E., & Loyd, J. E. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-383834-6.00065-3 · Cited by 3
Self-citationGenetic Underpinnings of Pulmonary Fibrosis: An Overview
Mahalanobish, S., Ghosh, S., & Sil, P. C. (2024) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/0118715257261006231207113809 · Cited by 3
Fernández-Varas, B., Manguán-García, C., Rodríguez-Centeno, J., Mendoza-Lupiáñez, L., Calatayud, J., Perona, R., Martín‐Martinez, M., Gutiérrez‐Rodríguez, M., Benitéz‐Buelga, C., & Sastre, L. (2024) · Human Molecular Genetics · doi:10.1093/hmg/ddae015 · Cited by 5
“…of the variants identified in AA or IPF patients like TERT p.Val84Glu, identified in a patient presenting leukoplakia and thrombopenia [41], TERT p.Val1090Met (AA) [32], TERC n.23G > C (IPF) [41] or TERC n.325G > T (IPF) [54] produced alterations in several of the others parameters analyzed.”
BackgroundInvestigational gene expression inhibitors for the treatment of idiopathic pulmonary fibrosis
Spagnolo, P., Tonelli, R., Mura, M., Reisman, W. M., Sotiropoulou, V., & Tzouvelekis, A. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2462592 · Cited by 3
“Even in the absence of telomerase mutations, IPF patients have telomeres shorter than healthy individuals [14].”
Peripheral blood telomere alterations in ground glass opacity (GGO) lesions may suggest malignancy
Koslow, M., Shitrit, D., Israeli‐Shani, L., Uziel, O., Beery, E., Osadchy, A., Refaely, Y., Shochet, G. E., & Amiel, A. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13026 · Cited by 3
Xu, J., de Oliveira, D. M., Trudeau, M. A., Yang, Y., Chin, J. J. Y., Sin, D. D., Sandford, A. J., & Wong, J. M. Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-83686-z · Cited by 3
Noh, S., Bertini, C. D., Mira-Avendano, I. C., Kaous, M., Patel, B., Faiz, S. A., Shannon, V. R., Balachandran, D. D., Bashoura, L., Adachi, R., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6396 · Cited by 3
“Architectural distortion 12 (18) 7 (29)”
The Role of Tyrosine Kinases in the Pathogenesis and Treatment of Lung Disease
Lam, J., & Stewart, J. (2012) · InTech eBooks · doi:10.5772/37901 · Cited by 3
“, 2011) and human telomerase reverse transcriptase (TERT) and telomerase RNA component (TERC) (Alder et al., 2008; Armanios et al., 2007; Cronkhite et al., 2008; Tsakiri et al., 2007).”
BackgroundGarcia, C. K. (2012) · Proceedings of the American Thoracic Society · Cited by 3
Pulmonary Evaluation of Liver Transplant Candidates
DuBrock, H. M., & Krowka, M. J. (2019) · Springer eBooks · doi:10.1007/978-3-319-92934-7_2 · Cited by 3
Immunohistochemistry and Molecular Biology in Transbronchial Cryobiopsies
Chilosi, M., Marcolini, L., Caliò, A., & Poletti, V. E. (2019) · Springer eBooks · doi:10.1007/978-3-030-14891-1_9 · Cited by 4
Targeting Senescent Cells to Improve Human Health
Wijshake, T., & van Deursen, J. M. A. (2016) · Healthy ageing and longevity · doi:10.1007/978-3-319-26239-0_16 · Cited by 3
“A small percentage of IPF patients have short telomeres, in some cases due to mutations in telomerase or telomerase RNA (Armanios et al. 2007; Alder et al. 2008).”
BackgroundChambers, D. C. (2015) · Respirology · doi:10.1111/resp.12580 · Cited by 3
Xue, J., & Duncan, S. R. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.179.9.852 · Cited by 3
Size matters! Peripheral blood leukocyte telomere length and survival after critical illness
Mayr, F., & Yende, S. P. (2020) · European Respiratory Journal · doi:10.1183/13993003.02114-2019 · Cited by 3
Longhorne, F. L., Wilkinson, H. N., Hardman, M. J., & Hart, S. P. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.29.470337 · Cited by 3
Cui, B., Chen, Y., Ma, X., Yin, G., & Xie, Q. (2022) · Research Square · doi:10.21203/rs.3.rs-1414064/v1 · Cited by 3
Juan-Guardela, B. M., & Herazo-Maya, J. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag121 · Cited by 3
Fibrotic Signaling in the Lung
Dutta, J. A., Bahudhanapati, H., Tan, J., Goldblum, A., & Kass, D. J. (2018) · Molecular and translational medicine · doi:10.1007/978-3-319-98143-7_4 · Cited by 2
Gene polymorphisms and risk of idiopathic pulmonary fibrosis: a systematic review and meta-analysis
Hassan, M., Ali, A. S., Zubairi, A. B. S., Padhani, Z. A., Kirmani, S., Ahmad, H., Fatmi, Z., & Das, J. K. (2024) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2024.2952 · Cited by 2
Vilstrup, E., Prior, T. S., Kreuter, M., Wuyts, W. A., Molina‐Molina, M., Wijsenbeek, M. S., Morais, A., Tzouvelekis, A., Ryerson, C. J., Caro, F. M., et al. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03532-0 · Cited by 5
Telomere biology disorder presented with de novo pneumocystis jirovecii pneumonia: A case report
Hamad, A., Joudeh, N., Saeed, A. M., Omar, A., Ibraheem, M., & AZAR, J. J. (2025) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2025.102313 · Cited by 2
“These genetic mutations accelerate cellular aging in lung tissue, impairing its ability to heal after injury, a mechanism first detailed in foundational studies by Alder et al. [20].”
The role of epigenetic regulation in idiopathic pulmonary fibrosis
Li, R. M., Stentenbach, M., Tan, D. B. A., Ludewick, H. P., Walters, E. H., Clynick, B., & Moodley, Y. P. (2025) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00030.2025 · Cited by 3
The intersection of liver cirrhosis and pulmonary fibrosis
Bayraktar, E. A., & Salvatore, M. M. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07449-4 · Cited by 4
“There have been reports of both diseases co-occurring in patients with TERT mutations and/or short telomeres [75–77] (Fig.”
Cellular profiling identifies an early profibrotic alveolar type 2 cell signature in lung fibrosis
Naikawadi, R. P., Bazarov, A. V., Wax, M., Boostanpour, K., Kukreja, J., Traglia, M., Agrawal, A., Thomas, R., Bhattacharya, M., & Wolters, P. J. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag044 · Cited by 4
Interstitial lung abnormalities: to treat or not to treat? The hamlet dilemma
Zanini, U., Franco, G., Pirotta, C., Passeri, E., Mazzotta, S. M., Ferrara, G., Mura, M., Faverio, P., & Luppi, F. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1762243 · Cited by 2
Familial interstitial lung disease: emerging insights into screening and genetic risk
Cristancho, A. P. H., Planas‐Cerezales, L., Molina‐Molina, M., Borie, R., Wuyts, W. A., Jodar, M., Sellarés, J., & Hernández‐González, F. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1747200 · Cited by 3
Elliot, S. J., Grimaldo, S., Catanuto, P., Pereira‐Simon, S., Xia, X., Civettini, G., Shahzeidi, S., Pastar, I., Tomic‐Canic, M., & Glassberg, M. K. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102927 · Cited by 3
“22 We recognize, however, that further investigation of exosome effects on telomere biology is best conducted in human fibrotic lung tissue 77 and is ongoing in our laboratory.”
Progressive pulmonary fibrosis: current perspectives in diagnostic imaging
Agarwal, P., Schlett, C. L., Bamberg, F., & Frye, B. C. (2024) · BJR|Open · doi:10.1093/bjro/tzaf018 · Cited by 2
“15 Lower baseline lung function in certain ILDs like f-HP and systemic sclerosis-associated ILD and smoking history in RA-ILD have been shown to be associated with a higher risk of progression.”
Barbé‐Tuana, F. M., Grün, L. K., Pierdoná, V., de Oliveira, B. C. D., de Paiva, S. C., Shiburah, M. E., da Silva, V. L., Morea, E. G. O., Fontes, V. S., & Cano, M. I. N. (2021) · Springer eBooks · doi:10.1007/978-3-030-73151-9_7 · Cited by 4
Extra-Telomeric Effects of Telomerase (hTERT) in Cell Death
Bellot, G. L., & Wang, Y. (2013) · InTech eBooks · doi:10.5772/48583 · Cited by 2
“More recently it was observed that mutations in telomerase components TERT or TERC may be linked in the occurrence of the idiopathic pulmonary fibrosis resulting in dramatic destruction of lung tissues (Alder et al., 2008; Tsakiri et al., 2007).”
BackgroundTelomerase and Human Disease: The Beginnings of the Ends?
Fossel, M., & Flanary, B. E. (2009) · Rejuvenation Research · doi:10.1089/rej.2009.0873 · Cited by 3
“…reflux, 24 human immunodeficiency virus (HIV), 25,26 rheumatoid arthritis, systemic lupus, chronic hepatitis, dystrophy, myelodysplastic syndrome, congenital dyskeratosis, 27,28 idiopathic pulmonary fibrosis, 29,30 cardiac hypertrophy, a number of anemias, Down syndrome, and ataxia telangectasia.”
Shivshankar, P. (2012) · ISRN Inflammation · doi:10.5402/2012/267101 · Cited by 4
“Lymphocytic inflammation of the lungs and foci of proliferating fibroblasts with atypical interstitial pneumonia are used in the diagnosis of pathophysiology of the disease.”
BackgroundAging and IPF: What Is the Link?
Selman, M., Romero, Y., & Pardo, A. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_12 · Cited by 2
Genetic Testing in Interstitial Lung Disease: Potential Benefits and Unintended Risks
Krishna, R. (2023) · Current Pulmonology Reports · doi:10.1007/s13665-023-00322-z · Cited by 2
“Also, when short telomeres are noted, the presence of identified mutations in the telomere-related genes is not always seen [25, 33, 34].”
BackgroundAging and Chronic Respiratory Diseases: Novel Mechanisms
Sellarés, J., & Rojas, M. (2017) · Barcelona Respiratory Network · doi:10.24875/brn.m17000003 · Cited by 2
Alvarado, A. (2018) · Clinical Research and Trials · doi:10.15761/crt.1000241 · Cited by 2
“Shortened telomeres, oxidative stress, proteostatic dysregulation, endoplasmic reticulum stress, and mitochondrial dysfunction decrease epithelial alveolar cell proliferation and increase the secretion of profibrotic mediators [68,69].”
BackgroundGenetics of Pulmonary Fibrosis
Adams, T. N., & Garcia, C. K. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_8 · Cited by 3
Biomarkers in Interstitial Lung Diseases
Fernandez, I. E., & Eickelberg, O. (2020) · Respiratory medicine · doi:10.1007/978-3-030-31507-8_11 · Cited by 2
Recognizing genetic disease: A key aspect of pediatric pulmonary care
Yonker, L. M., Hawley, M. H., Moschovis, P. P., Lu, M., & Kinane, T. B. (2020) · Pediatric Pulmonology · doi:10.1002/ppul.24706 · Cited by 3
The future is here: Integrating genetics into the pediatric pulmonary clinic
Hawley, M. H., Moschovis, P. P., Lu, M., Kinane, T. B., & Yonker, L. M. (2020) · Pediatric Pulmonology · doi:10.1002/ppul.24723 · Cited by 3
Epidemiology of Idiopathic Pulmonary Fibrosis
Patil, S. M. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98482 · Cited by 4
“Many IPF patients have a shorter telomere with no detectable mutation in telomerase [15].”
BackgroundTelomere length and survival in IPF patients – Reply
Dai, J., & Gao, Q. (2015) · Respirology · doi:10.1111/resp.12666 · Cited by 2
Sánchez-Vazquez, R., García-Oteyza, S. B., Serrano, R., Flores, J. M., Martínez, P., & Blasco, M. A. (2025) · Genes & Development · doi:10.1101/gad.352855.125 · Cited by 2
“Among the telomere syndromes, IPF is the most common condition associated with telomere dysfunction in humans, and 8% – 15% of familial cases have been linked to telomerase mutations in either TERT or TERC (Armanios et al. 2007; Alder et al. 2008).”
Alber, A. B., Kwong, G., Gupta, V. K., Dooley, P. E., Patel, J., Bawa, P., Minakin, K., Jones, D. L., Gopal, D., Souza, H., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.30.702837 · Cited by 4
Interstitial Lung Abnormalities (ILA) and Pulmonary Fibrosis
Wada, N., Lee, K. S., & Hatabu, H. (2024) · Current Pulmonology Reports · doi:10.1007/s13665-024-00350-3 · Cited by 1
“More than half of FIP patients with telomerase mutations, approximately half of sporadic IPF patients, and 10% of patients with other IIPs were reported to have telomere length in leukocytes or lymphocytes below the 10th age-adjusted percentile [71, 74].”
Prognosis and prognostic factors for chronic fibrosing idiopathic interstitial pneumonias
Nishikiori, H., & Chiba, H. (2025) · Respiratory Investigation · doi:10.1016/j.resinv.2025.06.005 · Cited by 2
Leukocyte telomere length and lung function: a mendelian randomization study in European population
Zhu, S., Zheng, W., Rao, D., Tang, Z., & Liao, X. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1373064 · Cited by 1
de Castro, M. C. S., Costa1, L. D. C., Salum, K. C. R., de Castro, H. A., Ribeiro, P. C., Costa, W., Nani, Â. S. F., & Kohlrausch, F. B. (2024) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20240318 · Cited by 1
“(15) Several lung diseases have been studied to evaluate the impact on TL, including interstitial lung diseases, (16,17) idiopathic pulmonary fibrosis, (10,18,19) COPD, (17,20) and COVID-19.”
Telomere Shortening in Interstitial Lung Disease: Challenges and Promises
Jin, H., Song, J., Gao, R., Sha, B., Wang, S., Luo, P., Yu, L., Xu, X., & Wang, X. (2025) · The Clinical Respiratory Journal · doi:10.1111/crj.70103 · Cited by 1
“Also, telomere lengths in alveolar epithelial cells and peripheral blood leukocytes from the same patients were compared, and a positive correlation was found between the presence of telomere shortening in peripheral leukocytes and in alveolar epithelial cells [14].”
InfluentialExploring the uncharted role of cell senescence in rare diseases
Selvaggio, P., Taci, E., Barassi, A., Massa, V., Gervasini, C., Lesma, E. A., Bernardelli, C., & Fede, E. D. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03778-1 · Cited by 1
“A significant shortening of telomere length in peripheral blood cells of IPF patients compared to age-matching controls results from the TERT and TERC mutations, but it is also observed in absence of any telomerase mutation [119, 120].”
Genetic Familial Interstitial Lung Disease
Fernandez, R. J., & Kropski, J. A. (2025) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2025.07.008 · Cited by 1
Climate Change and the Impact On Interstitial Lung Diseases
Ahluwalia, B., & Singh, S. (2026) · Pulmonary Therapy · doi:10.1007/s41030-026-00347-0 · Cited by 3
A syndromic framework for progressive pulmonary fibrosis
Perrotta, F., Luppi, F., Sebastiani, M., & Bianco, A. (2026) · Respiratory Research · doi:10.1186/s12931-026-03649-8 · Cited by 1
“…Regulator of telomere elongation helicase 1; SFTPC: Surfactant protein C; TERT: Telomerase reverse transcriptase; TGF-β – Transforming growth factor beta they plausibly lower the threshold for irreversible fibrosis and accelerate functional decline once fibrotic remodelling is established [15, 17].”
Baurzhan, M. B., Gulyayev, A. E., Absattarova, K. S., Kairgeldina, S. A., Аbzaliyev, K., Izbassarova, A., Lepessova, M., & Absatarova, K. (2026) · Diseases · doi:10.3390/diseases14060201 · Cited by 3
“Germline mutations in telomerase components (TERT, TERC), together with accelerated telomere shortening, have been identified in both familial and sporadic cases of the disease [17,18].”
Performance of age-adjusted whole genome sequencing telomere length in idiopathic pulmonary fibrosis
Kim, J. S., Receveur, B. A., Zhang, D., Ma, S.-F., Huang, Y., McGroder, C. F., Putman, R. K., Podolanczuk, A. J., Rotter, J. I., Rich, S. S., et al. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag259 · Cited by 1
Schratz, K. E., & Armanios, M. Y. (2026) · NEJM Evidence · doi:10.1056/evidra2600012 · Cited by 2
Self-citationHow telomere attrition protects against cancer
Stuart, A., Zhang, B., Hockemeyer, D. F., & de Lange, T. (2026) · Nature Reviews Genetics · doi:10.1038/s41576-026-01001-w · Cited by 1
“It is also noteworthy that in patients with TBDs, lung, oesophageal and oral cells are often affected 64,65 , as would be expected if the short telomeres activate ATM more readily in the high oxygen environment of these organs.”
New Aspects of Idiopathic Pulmonary Fibrosis
Molina‐Molina, M., Vicens, V., & Estany, S. (2010) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0b013e3181e4bb22 · Cited by 1
“It has been suggested that a short telomerase could be a risk factor in developing IPF.12”
BackgroundInfluentialCarulli, L., Anzivino, C., Bertolotti, M., Loria, P., Richeldi, L., & Cerri, S. (2014) · Case Reports in Internal Medicine · doi:10.5430/crim.v2n1p11 · Cited by 1
“For example, patients with pulmonary fibrosis who have mutant telomerase genes are at an increased risk of developing bone marrow failure and liver disease [13, 17] as well as individuals with aplastic anemia have an increased incidence of pulmonary fibrosis when they are exposed to pulmonary toxic drugs in the bone m…”
Idiopathic Pulmonary Fibrosis: Stem Cell-Mediated Therapeutic Approach
Totey, S. M. (2017) · Springer eBooks · doi:10.1007/978-981-10-3701-6_29 · Cited by 1
Kokosi, M. A., Renzoni, E. A., & Bonella, F. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10005515 · Cited by 1
Borie, R., Kannengiesser, C., Nathan, N., & Crestani, B. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10004715 · Cited by 1
Epidemiology and Risk Factors For Interstitial Lung Diseases
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4644-4 · Cited by 1
Accelerated biological ageing in familial pulmonary fibrosis
Serezani, A. P. M., Mitchell, D. B., Cogan, J. D., Malabanan, M. M., Markin, C. R., Garnett, E. T., Douglas, K., Fadely, T. H., Kropski, J. A., Salisbury, M. L., et al. (2025) · European Respiratory Journal · doi:10.1183/13993003.02427-2024 · Cited by 1
Self-citationAll in the Family: Role for Precision Medicine in Screening and Disease Course Prediction
Pearmain, L., Callum, J., Stanel, S. C., & Rivera‐Ortega, P. (2025) · Respiratory medicine · doi:10.1007/978-3-031-87183-2_2 · Cited by 1
Telomere biology disorders as an example of rare disease advocacy
Stevens, K. B., Raj, H. A., Paxton, J. K., & Longhurst, H. J. (2025) · Seminars in Hematology · doi:10.1053/j.seminhematol.2026.04.002 · Cited by 1
El papel del factor inducible por hipoxia 1 (HIF-1) en la fibrosis pulmonar idiopática
Aquino‐Gálvez, A., & González-Ávila, G. (2010) · NCT Neumología y Cirugía de Tórax · Cited by 3
Management of a patient with familial idiopathic pulmonary fibrosis.
Böing, S., George, S., & Hagmeyer, L. (2013) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 1
Review of the British Thoracic Society Winter Meeting 2013, 4–6 December, London, UK
Chalmers, J. D., Greening, N. J., José, R. J. P., & Janes, S. M. (2014) · Thorax · doi:10.1136/thoraxjnl-2014-205177 · Cited by 2
Epidemiology and Risk Factors of IPF: Can We Dare to Ask, “What Are the Possible Causes?”
Kuwano, K., Araya, J., & Hara, H. (2015) · Springer eBooks · doi:10.1007/978-4-431-55582-7_2 · Cited by 4
Khattar, E., & Tergaonkar, V. (2016) · InTech eBooks · doi:10.5772/62130 · Cited by 1
Drug Discovery in Tissue Fibrosis
Pinto, S., Hoek, M., Huang, Y., Costet, P., Ma, L., & Imbriglio, J. E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12432-1 · Cited by 2
Idiopathic Pulmonary Fibrosis: Clinical Behavior, Pathogenic Mechanisms and Therapeutic Approach
Selman, M., & Pardo, A. (2015) · Barcelona Respiratory Network · doi:10.23866/brnrev:2015-m0003 · Cited by 1
Traitement de la fibrose pulmonaire idiopathique
Valeyre, D., & Dion, G. (2010) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)32328-3 · Cited by 1
Genetic Determinants of Interstitial Lung Diseases
Mathai, S. K., Schwartz, D. A., & Borie, R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812532-8.00015-x · Cited by 1
Kawabata, Y. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.89247 · Cited by 1
Idiopathic Interstitial Pneumonias
Ryu, J. H., Selman, M., Colby, T. V., & King, T. E. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00063-4 · Cited by 2
Fibrosing pneumonia – how to diagnose, and how to recognize the etiology?
Popper, H. (2020) · Surgical and Experimental Pathology · doi:10.1186/s42047-020-00067-y · Cited by 1
Idiopatic pulmonary fibrosis: A simple approach to a complex problem
Alvarado, A. (2020) · Clinical Research and Trials · doi:10.15761/crt.1000309 · Cited by 1
“Shortened telomeres, oxidative stress, proteostatic dysregulation (abnormalities in the synthesis, trafficking, folding, or turnover of intracellular proteins), endoplasmic reticulum stress, and mitochondrial dysfunction decrease alveolar cell proliferation and increase the secretion of profibrotic mediators [21,22].”
BackgroundRare Diffuse Lung Diseases of Genetic Origin
Spagnolo, P. (2014) · Springer eBooks · doi:10.1007/978-1-4471-2401-6_36 · Cited by 1
A pathophysiologic evaluation of the receptor for advanced glycation end products (RAGE) in the lung
Englert, J. M. (2009) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 1
Aging Mesenchymal Stem Cells in Lung Disease
Kapetanaki, M. G., Mora, A. L., & Rojas, M. M. (2014) · Wiley eBooks · doi:10.1002/9781118396292.ch12 · Cited by 1
Fibrose hépatique : vive la sénescence !
Gilgenkrantz, H. (2009) · médecine/sciences · doi:10.1051/medsci/2009252137 · Cited by 1
Marinicak, S. J., & Lomas, D. A. (2017) · Wiley eBooks · doi:10.1002/9780470015902.a0005517.pub3 · Cited by 1
Epithelial biology in idiopathic pulmonary fibrosis
Selman, M., & Pardo, A. (2015) · doi:10.2217/fmeb2013.13.307 · Cited by 1
Xu, J., Trudeau, M. A., Sandford, A. J., & Wong, J. M. Y. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/552133 · Cited by 1
“Patients with mutations in TERT suffer from IPF in an autosomal dominant pattern due to telomerase haploinsufficiency and the consequent short telomere-induced tissue renewal defects [8].”
BackgroundMethodInfluentialRedox regulation in pulmonary fibrosis: towards therapeutic targets
Veith (2019) · Research Publications (Maastricht University) · doi:10.26481/dis.20190524cv · Cited by 1
Metadata
- Authors
- Alder, J. K., Chen, J. J.-L., Lancaster, L., Danoff, S., Su, S.-C., Cogan, J. D., Vulto, I., Xie, M., Qi, X., Tuder, R. M., Phillips, J. A., Lansdorp, P. M., Loyd, J. E., & Armanios, M. Y.
- Affiliations
- Johns Hopkins University (US)
- Arizona State University (US)
- Vanderbilt University (US)
- BC Cancer Agency (CA)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-09-02
- Volume
- 105
- Issue
- 35
- Pages
- 13051-13056
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2529100
- OpenAlex
- W2147238277
- Cited by
- 805
- References
- 35
- Citations by year
- 2026: 32 · 2025: 40 · 2024: 38 · 2023: 48 · 2022: 45 · 2021: 61 · 2020: 53 · 2019: 60 · 2018: 54 · 2017: 40 · 2016: 36 · 2015: 56 · 2014: 45 · 2013: 45 · 2012: 40
- FWCI
- 33.48
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Doris Duke Charitable Foundation
- Johns Hopkins University
- National Institutes of Health
- U.S. Public Health Service (T32 60441, K08 118416)
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- idiopathic pulmonary fibrosis, idiopathic interstitial pneumonia, telomere length, short telomeres, telomerase mutations, hTERT, hTR, leukocytes, alveolar epithelial cells, cryptogenic cirrhosis, disease risk
- MeSH terms
- Epithelium, Family, Fibrosis, Heterozygote, Humans, Leukocytes, Mononuclear, Pulmonary Alveoli, Pulmonary Fibrosis, Risk Factors, RNA, Tomography, X-Ray Computed, Biomarkers, Case-Control Studies, Telomere, In Situ Hybridization, Fluorescence, Germ-Line Mutation, Telomerase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.